Candriam S.C.A. Trims Stake in Amgen Inc. $AMGN

Candriam S.C.A. lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 0.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 505,720 shares of the medical research company’s stock after selling 483 shares during the quarter. Amgen makes up 0.8% of Candriam S.C.A.’s portfolio, making the stock its 21st largest holding. Candriam S.C.A. owned 0.09% of Amgen worth $141,208,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Nuveen LLC bought a new position in shares of Amgen during the 1st quarter valued at approximately $688,868,000. Federated Hermes Inc. boosted its position in shares of Amgen by 48.5% in the first quarter. Federated Hermes Inc. now owns 2,037,169 shares of the medical research company’s stock worth $634,680,000 after purchasing an additional 665,555 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Amgen by 128.9% in the first quarter. The Manufacturers Life Insurance Company now owns 1,065,694 shares of the medical research company’s stock worth $332,017,000 after purchasing an additional 600,096 shares in the last quarter. WoodTrust Financial Corp lifted its stake in shares of Amgen by 8,223.6% during the 2nd quarter. WoodTrust Financial Corp now owns 595,634 shares of the medical research company’s stock valued at $166,307,000 after buying an additional 588,478 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC bought a new position in Amgen in the 2nd quarter worth $156,812,000. 76.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on AMGN shares. Piper Sandler reissued an “overweight” rating on shares of Amgen in a research note on Wednesday, November 5th. Weiss Ratings raised shares of Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Amgen from $280.00 to $285.00 and gave the stock a “hold” rating in a research note on Tuesday. Finally, Guggenheim raised their price objective on Amgen from $288.00 to $305.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. Seven investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Amgen presently has an average rating of “Hold” and an average price target of $307.94.

Amgen Stock Performance

Amgen stock opened at $336.28 on Thursday. The company’s 50-day moving average price is $292.73 and its 200-day moving average price is $289.69. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. The company has a market cap of $181.08 billion, a PE ratio of 27.50, a price-to-earnings-growth ratio of 2.61 and a beta of 0.45. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $342.40.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. The firm had revenue of $9.56 billion during the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter last year, the firm earned $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, equities research analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, December 12th. Stockholders of record on Friday, November 21st will be issued a $2.38 dividend. The ex-dividend date is Friday, November 21st. This represents a $9.52 dividend on an annualized basis and a dividend yield of 2.8%. Amgen’s payout ratio is 73.57%.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the sale, the senior vice president owned 7,209 shares in the company, valued at approximately $2,141,000.91. This represents a 14.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.69% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.